Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determine its role in resistance to the anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will correlate with resistance to anti-androgen therapies, as has been documented in prostate cancer, and this can be used to select patients most likely to benefit from these therapies in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer will be enrolled and be on study for about 3 days.

NCT Number	NCT04573231
Lead Sponsor	University of Wisconsin, Madison
Conditions	Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Enrollment	13 participants
Start Date	2021-05-24
Primary Completion	2026-08 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-07